Evotec SE EVT
XETR · Germany · Commercial Services
€3.03-0.07 (-2.32%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Funds will advance novel class of RNA inhibitors to reverse intractable genetic conditions Seed led by 4BIO Capital with follow-on participation from the company's original pre-seed investor EXTEND (CDP Venture Capital SGR, Angelini Ventures and Evotec SE) Science originates from three leading institutions – the Beth Israel Deaconess Medical Center, the Italian Research National Council (CNR) and the Cancer Science Institute of Singapore London, United Kingdom, 29 September 2026 – 4BIO Capital,
Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026. The decision for Dr. Dohrmann to step down from his position was made by mutual consent between Dr. Dohrmann and the Company.
Giovanni Amabile, Founder and CEO Giovanni Amabile, Founder and CEO of Aptadir Therapeutics Funds will advance novel class of RNA inhibitors to reverse intractable genetic conditions Seed is led by 4BIO Capital with follow-on participation from the company's original pre-seed investor EXTEND (CDP Venture Capital SGR, Angelini Ventures and Evotec SE) Science originates from three leading institutions – the Beth Israel Deaconess Medical Center, the Italian Research National Council (CNR) and the C
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.